# INTERVIEW: Immupharma Plc “Grossly undervalued and the time is now”

- Link: https://www.directorstalkinterviews.com/interview-immupharma-plc-grossly-undervalued-time-now/412731267
- Published: 2017-07-04T07:29:27+01:00
- Author: Giles Arbor

**Immupharma Plc** (LON:IMM) is the topic of conversation when Head of Research 
at Northland Capital Partners Vadim Alexandre caught up with DirectorsTalk. Vadim
provides his thoughts on the key points highlighted in the report, explains the 
rational behind the rise in target price, the importance of investor events and 
tells us why he thinks investors should buy Immuphrama shares.

 

ImmuPharma Plc is a pharmaceutical development company listed since 2006 on AIM 
of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with
high sales potential in specialist markets with serious unmet need. ImmuPharma is
led by a commercially focused Board and management team with extensive experience.

ImmuPharma announced on 1 March 2016 the successful completion of a £8.4 million
fund raise, comprising a Placing and Subscription together with confirmation of 
EIS and VCT qualifying status. Monies raised will principally be used to complete
the pivotal Phase III trial of Lupuzor™. Following the issue of the New Ordinary
Shares ImmuPharma has 121,781,219 ordinary shares of 10 pence each (the “Ordinary
Shares”) in issue.

**Lupuzor™**

Lupuzor™ (also referred to as Forigerimod, or P140) is ImmuPharma’s lead compound
and a potential treatment for lupus (or Systemic Lupus Erythematosus), a chronic,
potentially life-threatening auto-immune disease. Lupuzor™ has a novel mechanism
of action aimed at modulating the body’s immune system so that it does not attack
healthy cells, and avoids causing adverse side effects. It has the potential to 
halt the progression of the disease in a substantial proportion of patients.

Lupuzor™ has been granted Fast Track status by the US FDA and approval to start 
Phase III under Special Protocol Assessment (SPA). This SPA was subsequently amended
due to its strong safety and efficacy profile to allow for a reduced number of patients
in the pivotal Phase III trial thereby reducing the projected cost and time of development
considerably.

The pivotal Phase III clinical study is entitled “A 52-Week, Randomized, Double-
Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety
of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic 
Lupus Erythematosus”. It is a pivotal study designed to demonstrate the safety and
efficacy of IPP-201101 and as a last step prior to the filing of the drug for approval
with the US Food & Drug Administration (“FDA”) and the European Medicines Agency(“
EMA”). For more information please visit: www.ClinicalTrials.gov/lupuzor

**Commercial Opportunity**

There are an estimated five million people globally suffering from Lupus, with approximately
1.5 million patients in the US, Europe and Japan (Source: Lupus Foundation of America).
Current ‘standard of care’ treatments, including steroids and immunosuppressants,
can potentially have either serious side effects for patients or limited effectiveness,
with over 60% of patients not adequately treated. GSK’s Benlysta is the first Lupus
drug approved in over 50 years and paves the path to market for Lupuzor™. Based 
on conservative estimates, and taking into account that Benlysta is priced currently
at approximately $35,000 per patient per year, Lupuzor™ would be entering a market
with the potential for multi-billion dollar sales.

Share on: